WALDENSTRÖM MACROGLOBULINEMIA
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Oral drug combo tested for rare blood cancer
Disease control CompletedThis study tested whether a combination of oral drugs (thalidomide, cyclophosphamide, and dexamethasone) could effectively treat newly diagnosed Waldenström Macroglobulinemia, a rare blood cancer. It involved 44 patients who had not received standard treatments. The goal was to s…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Trial tests aggressive stem cell treatment for rare blood cancer
Disease control CompletedThis study aimed to see if a patient's own stem cells, collected and transplanted back after high-dose chemotherapy, works better than standard chemotherapy alone for people with high-risk Waldenström macroglobulinemia, a rare blood cancer. It involved 70 patients in China who ha…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Head-to-Head trial tests drug combos for rare blood disorder
Disease control CompletedThis study compared two different drug combinations for treating newly diagnosed Waldenström macroglobulinemia, a rare and slow-growing blood cancer. It involved 35 patients across multiple hospitals in China. The goal was to see which combination was better at controlling the di…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE4 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Oral combo aims for deep remission in rare blood cancer
Disease control CompletedThis study tested a combination of three oral drugs—zanubrutinib, ixazomib, and dexamethasone—for people newly diagnosed with symptomatic Waldenström Macroglobulinemia, a rare blood cancer. The goal was to see if this time-limited regimen (given for up to 24 months) could achieve…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
Early trial tests new combo for tough blood cancers
Disease control CompletedThis early-stage study tested the safety and initial effectiveness of combining two drugs, acalabrutinib and pembrolizumab, for people with various blood cancers. It involved 161 participants with conditions like lymphoma and leukemia. The main goal was to see if the combination …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA
Phase: PHASE1, PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC